Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., ...Daha Fazla

LANCET ONCOLOGY, cilt.19, sa.11, ss.1437-1448, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/s1470-2045(18)30739-3
  • Dergi Adı: LANCET ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1437-1448
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population.